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ABSTRACT
Background There are few therapeutic options available for 
patients with B- cell acute lymphoblastic leukemia (B- ALL) 
relapsing as CD19– either after chemotherapy or CD19- 
targeted immunotherapies. CD22- chimeric antigen receptor 
(CAR) T cells represent an attractive addition to CD19- CAR 
T cell therapy because they will target both CD22+CD19– 
B- ALL relapses and CD19– preleukemic cells. However, 
the immune escape mechanisms from CD22- CAR T cells, 
and the potential contribution of the epitope binding of the 
anti- CD22 single- chain variable fragment (scFv) remain 
understudied.
Methods Here, we have developed and comprehensively 
characterized a novel CD22- CAR (clone hCD22.7) targeting 
a membrane- distal CD22 epitope and tested its cytotoxic 
effects against B- ALL cells both in in vitro and in vivo 
assays.
Results Conformational epitope mapping, cross- blocking, 
and molecular docking assays revealed that the hCD22.7 
scFv is a high- affinity binding antibody which specifically 
binds to the ESTKDGKVP sequence, located in the Ig- like 
V- type domain, the most distal domain of CD22. We observed 
efficient killing of B- ALL cells in vitro, although the kinetics 
were dependent on the level of CD22 expression. Importantly, 
we show an efficient in vivo control of patients with B- ALL 
derived xenografts with diverse aggressiveness, coupled 
to long- term hCD22.7- CAR T cell persistence. Remaining 
leukemic cells at sacrifice maintained full expression of 
CD22, ruling out CAR pressure- mediated antigen loss. Finally, 
the immunogenicity capacity of this hCD22.7- scFv was very 
similar to that of other CD22 scFv previously used in adoptive 
T cell therapy.
Conclusions We report a novel, high- affinity hCD22.7 scFv 
which targets a membrane- distal epitope of CD22. 4- 1BB- 
based hCD22.7- CAR T cells efficiently eliminate clinically 
relevant B- CD22high and CD22low ALL primary samples in 
vitro and in vivo. Our study supports the clinical translation of 
this hCD22.7- CAR as either single or tandem CD22–CD19- 
CAR for both naive and anti- CD19- resistant patients with 
B- ALL.
BACKGROUND
B- cell acute lymphoblastic leukemia (B- ALL) 
is an aggressive cancer, diagnosed at any age 
throughout the lifespan of an individual, 
being the most common malignancy in 
children.1 Despite current 5- year disease- 
free survival rates of ~80%, refractory and 
relapsed (R/R) patients have a dismal prog-
nosis.2–7 Adult B- ALL is less frequent, but is 
commonly associated with an unfavorable 
clinical outcome even after the use of high- 
dose chemotherapy regimens and allogenic 
stem cell transplantation.8
Immunotherapy has generated unprec-
edented expectations in cancer treatment. 
Adoptive cellular immunotherapy, based on 
the genetic engineering of human T cells 
with chimeric antigen receptors (CARs) redi-
rected against cell surface tumor antigens, 
has shown great potential in R/R B- ALL 
due to the high efficacy and specificity of 
CD19- CAR T cells, with ~90% response rates 
and ~50% complete remission rates after 12 
months.9 10 However, CD19- CAR T cells are 
not always curative and ~60% of patients 
inevitably relapse, mainly because of poor 
CAR T cell persistence or the emergence 
of CD19– B- ALL clones.11 12 Of note, a very 
recent and elegant clinical study has shown 
that a low- affinity CD19- CAR enhances CAR 
T cell expansion and persistence in patients 
with B- ALL, but it is associated with immune 
escape and an increased number of CD19– 
relapses.12 Unfortunately, there are very few 
therapeutic options for patients with B- ALL 
relapsing as CD19– after either chemotherapy 
or CD19- directed immunotherapy and, there-
fore, novel strategies are being explored to 
enhance CAR T cell function and persistence, 
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including the development of novel target antigens, 
costimulatory domains or effector cells.13
Like CD19, CD22 is expressed in a B- cell lineage- 
restricted fashion.14 CD22- directed T cells are an attrac-
tive addition to the current CD19- directed T cell strategies 
because (1) they constitute an alternative for CD19–/dim 
B- ALL relapses as CD22 is retained in such relapses,15 and 
(2) they would target the earliest pre- VDJ CD19–B- lineage 
progenitors, which potentially can escape in CD19- CAR 
T cell therapy.16 Indeed, CD22 has been employed as a 
target for B- ALL in clinical trials using anti- CD22 mono-
clonal antibodies (moAb) linked to immunotoxins,17–19 
and several CD22- CARs have also been reported.15 20–22 
CD22- CAR T cells induce clinical remission in ~70% 
of patients with R/R B- ALL either naive or resistant to 
CD19- CAR T cells.15 21 23 Moreover, these studies reported 
somewhat different clinical results regarding the poten-
tial mechanism of immune escape of B- ALL blasts from 
CD22- CAR T cells- mediated lysis with subsequent CD22–/
dim relapses.15 21 Importantly, comparative studies from 
the Orentas laboratory suggested that maximal efficacy 
of CD22- CAR T cells is obtained when using anti- CD22 
antibodies that target cell surface proximal epitopes or 
that display a high- binding affinity for CD22.20 Here, we 
have developed and characterized a novel high- affinity 
CD22- CAR targeting a membrane- distal CD22 epitope, 
and report an efficient elimination in vitro and in vivo of 
clinically relevant primary B- ALL cells.
MATERIALS AND METHODS
Generation of a CD22 single-chain variable fragment (scFv)
MoAbs reactive with human CD22 were generated by 
fusion of NS-1 myeloma cells with splenocytes from a 
Balb/c mouse previously immunized three times with 
30×106 CD22- transfected 300.19 cells. Supernatants 
from hybridoma- containing wells were screened by flow 
cytometry for moAbs reactive with CD22- transfected 
300.19 cells. Three reactive hybridomas were chosen for 
further characterization and were subcloned by limiting 
dilution (clones hCD22.7, hCD22.316 and hCD22.401). 
The three antibodies were IgG1κ isotype, as determined 
using a mouse moAb isotyping kit (Boehringer Mann-
heim, Mannheim, Germany). Antibody specificity was 
further validated using a CD22- transfected COS cell line 
(pUNO1- hCD22; InvivoGen, Toulouse, France), the cell 
lines Raji, Daudi, PRMI 82229, U266 and Jurkat, and 
peripheral blood (PB) mononuclear cells (PBMCs). CD22 
epitope binding to the hCD22.7 clone was determined 
by cross- blocking24 with an antibody against the N- ter-
minal domain of CD22 (S- HCL-1).25 The CD22- specific 
scFv derived from the hCD22.7 clone was obtained using 
the mouse IgG Library Primer Set (Progen, Heidelberg, 
Germany).
Immunogenicity prediction
Immunogenicity potential was predicted using the in 
silico tool NetMHC V.4.0.26 27 Analyzed scFvs were broken 
in 9- mer peptides, length for which human leukocyte 
antigen (HLA) molecules have a strong preference. 
Peptides were considered to bind major histocompat-
ibility complex class I (MHC- I) when a half- maximum 
inhibitory concentration (IC50) is <500 nM, being 
considered strong binders when IC50 <50 nM. Only HLA 
supertype representatives were analyzed. The predicted 
epitope- binding affinity was calculated as 1/IC50 100.
28
Epitope mapping
Reactivity of the hCD22.7 moAb was subjected to 
PEPperMAP Conformational Epitope Mapping against 
CD22 translated into cyclic constrained peptides 
(PEPperPRINT GmbH, Heidelberg, Germany). The 
sequence of CD22 (UniProtKB P20273) was elongated 
with neutral GSGSGSG linkers at the C- terminus and 
N- terminus to avoid truncated peptides. The elongated 
antigen sequence was translated into 7, 10 and 13 amino 
acid peptides with a peptide–peptide overlap of 6, 9 and 
12 amino acids. After peptide synthesis, all peptides were 
cyclized via a thioether linkage between a C- terminal 
cysteine and an appropriately modified N- terminus. The 
resulting conformational CD22 peptide microarrays 
contained 2556 different peptides printed in duplicate 
(5112 peptide spots), and were framed by additional 
human influenza hemagglutinin (HA, YPYDVPDYAG, 
146 spots) control peptides. Hibridoma supernatant 
containing hCD22.7 moAb was diluted in incubation 
buffer (phosphate- buffered saline (PBS), pH 7.4, with 
0.005% Tween 20) and 10% MB-070 blocking buffer 
(Rockland Immunochemicals, Limerick, Pennsylvania, 
USA) and incubated with peptide microarrays for 16 
hours at 4°C and swirling at 140 rpm. Unbound anti-
bodies were removed by washing the arrays with washing 
buffer (PBS, pH 7.4, with 0.005% Tween 20). Prestaining 
of the peptide arrays was done with 0.2 µg/mL goat anti- 
mouse IgG (H+L) antibody conjugated to DyLight680 
(Thermo Fisher Scientific). HA control peptides framing 
the peptide arrays were finally stained with 0.5 µg/mL 
monoclonal anti- HA (12CA5)- DyLight800 (Thermo 
Fisher Scientific) for 45 min at room temperature (RT). 
Quantification of spot intensities and peptide annotation 
was performed with the LI- COR Odyssey Imaging System 
(scanning offset 0.65 mm, resolution 21 µm, and scan-
ning intensities of 7/7 (red=700 nm/green=800 nm) and 
PepSlide Analyzer.
Structural model
The structural model of the CD22- hCD22.7- scFv complex 
was obtained using directed docking as follows. The 
structure for CD22 was taken for the PDB databank29 
(identification code 5vkj30) and the structure of the scFv 
anti- CD22 was derived by homology modeling using 
M4T31 and templates 4h0h,32 1dqd33 and 4okv.34 The 
initial docking conformations were inferred using Patch-
Dock35 by selecting the complementarity- determining 
regions of anti- CD22- scFv and mapped epitope of CD22 
as docking interfaces. Resulting docking conformations 
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were further refined and minimized using Rosetta36 and 
the top 200 poses were visually inspected. A more detailed 
description of the structural analysis is shown in online 
supplementary information.
CAR design and vectors, lentiviral production and T cells 
transduction
The CD22- specific scFv was cloned into a pCCL lentiviral- 
based backbone containing a human CD8 hinge and 
transmembrane (TM) domain, human 4- 1BB and CD3ζ 
endodomains (second- generation CAR), and a T2A- GFP 
cassette.37 An identical lentiviral vector with the CD8 
TM-4- 1BB- CD3ζ domains linked to a His- Tag was used as 
a mock intracellular (mock- IC) control. CAR- expressing 
viral particles pseudotyped with VSV- G were generated 
by cotransfection of HEK 293 T cells with the pCCL 
vector and the packaging plasmids VSV- G and psPAX2 
using polyethylenimine (PEI, Polysciences, Warrington, 
Pennsylvania, USA). Supernatants were collected at 48 
and 72 hours after transfection and concentrated by 
ultracentrifugation.
PBMCs were isolated from buffy coats from healthy 
volunteers by Ficoll- Hypaque gradient centrifugation 
(GE Healthcare, Chicago, Illinois, USA). Buffy coats were 
obtained from the Barcelona Blood and Tissue Bank on 
Institutional Review Board approval (HCB/2018/0030). 
T cells were activated by plate coating with anti- CD3 
(OKT3) and anti- CD28 (CD28.2) antibodies (BD Biosci-
ences, Franklin Lakes, New Jersey, USA) for 2 days and 
were transduced with the CAR- expressing lentivirus at a 
multiplicity of infection of 10 in the presence of inter-
leukin 7 (IL-7) and IL-15 (10 ng/mL; Miltenyi Biotec, 
Bergisch Gladbach, Germany).37 T cells were expanded 
in RPMI-1640 medium (Gibco/Invitrogen, Waltham, 
MA) containing 10% heat- inactivated fetal bovine serum 
(FBS, Sigma, St. Louis, Missouri, USA), penicillin- 
streptomycin (Gibco/Invitrogen), and IL-7 and IL-15 
(10 ng/mL), for up to 10 days. Surface expression of 
CD22- CAR was traced by fluorescence- activated cell 
sorting (FACS).
Cell lines
SEM, NALM6, MV4-11 and REH cells lines were 
purchased from the DSMZ cell line bank (Braunsch-
weig, Germany). CD19- knock out (KO) and CD22- KO 
SEM cells were generated by CRISPR- mediated genome 
editing. Briefly, 200,000 cells were electroporated 
(Neon transfector, ThermoFisher Scientific, Waltham, 
Massachusetts, USA) with a Cas9 protein/tracrRNA/
crRNA complex (IDT, Coralville, Iowa, USA). Two 
guides were designed for each gene: CD19- exon 2.1, 
CAGGCCTGGGAATCCACATG and CD19- exon 14.1, 
AGAACATGGATAATCCCGAT; and CD22- exon 3.2, 
TCAATGACAGTGGTCAGCTG and CD22- exon 9, 
CAGGTGTAGTGGGAGACGGG. After electroporation, 
cells were allowed to recover and then CD19– or CD22– 
cells were FACS sorted (>99% purity).
In vitro cytotoxicity assays and cytokine release 
determination
Target cells (cell lines or primary B- ALL cells; 100,000 
target cells/well of a 96- well plate) were incubated 
with CD22- CAR or mock- IC T cells at different effec-
tor:target (E:T) ratios for the indicated time periods. 
Cell lines were cultured in RPMI-1640, 10% FBS and 
penicillin–streptomycin. Primary cells were cultured 
in StemSpanTM SFEM media (StemCell Technologies, 
Vancouver, Canada), 20% FBS, penicillin–strepto-
mycin, insulin–transferrin–selenium (Gibco/Invit-
rogen), hSCF (100 ng/mL), hFLT3L (100 ng/mL), 
hIL3 (10 ng/mL) and hIL7 (10 ng/mL, all from 
Miltenyi Biotec, Bergisch Gladbach, Germany). CAR T 
cell- mediated cytotoxicity was determined by analyzing 
the residual live (7- aminoactinomycin D–; 7- AAD–) 
target cells at each time point and E:T ratio. For abso-
lute cell counting, BD TruCountTM absolute count 
tubes (BD Biosciences) were used. Quantification of 
the proinflammatory cytokines IL2, TNFα and IFNγ 
was measured by ELISA using BD OptEIATM Human 
ELISA kits (BD Biosciences), in supernatants harvested 
at 24 hours (cell lines) and 48 hours (primary cells) 
post T cell- exposure, using an 1:1 E:T ratio. Online 
supplementary table 1 shows clinic- biological features 
of the B- ALL samples used.
Flow cytometry
Cell surface expression of the CD22- CAR was confirmed 
by green fluorescence protein (GFP) expression, 
binding to an AffiniPure F(ab')₂ fragment goat anti- 
mouse IgG (H+L)- APC (Jackson ImmunoResearch, 
Westgrove, Pennsylvania, USA), and an anti- His- APC 
(J095G46; BioLegend, San Diego, California, USA), after 
prior incubation with human recombinant CD22- His 
(rCD22- His, ThermoFisher Scientific). Activation of 
transduced T cells was confirmed 48 hours after plating 
of PBMCs by surface staining with CD3- PE (UCHT1; 
BD Biosciences), CD25- APC (M- A251; BD Biosciences) 
and CD69- VioBlue (REA824; Miltenyi Biotec). T cells 
and target cells were identified in in vitro assays using 
the following human antibodies: CD3- PE (UCHT1), 
CD22- APC (HIB22), CD19- BV421 (HIB19) and CD10- 
PECy7 (HI10a) or CD13- PECy7 (WM15, for SEM cells) 
or CD33- APC (WM53, for MV4-11 cells, BD Biosci-
ences). Dead cells were discarded by 7AAD staining. 
Cells collected from mouse PB, bone marrow (BM) and 
spleen were stained with HLA- ABC- PE (G46-2.6), CD45- 
BV510 (HI30), CD3- PerCP (SK7), CD22- APC, CD19- 
BV421 and CD10- PECy7 (BD Biosciences). Cells were 
incubated for 30 min and then lysed and fixed with the 
BD FACSTM Lysing solution (BD Biosciences). Fluores-
cence Minus One controls were used to set the gates 
(online supplementary figure 1). A FACSCantoTM- II 
flow cytometer and a FACSDivaTM software was used for 
the analysis (BD Biosciences).
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In vivo xenograft models for B-ALL and CAR T cells
Twelve- week- old non- obese diabetic (NOD).Cg- Prk-
dcscid Il2rgtm1Wjl/SzJ (NSG) mice (The Jackson Labora-
tory, Bar Harbor, Maine USA) were bred and housed 
under pathogen- free conditions. All in vivo procedures 
were approved by a local ethics committee (HRH-17–
0029 P1). In total, 0.5–1.5×106 patient derived xeno-
graft (PDX) B- ALL cells were intra- BM transplanted 
in sublethally irradiated (2 Gy) NSG mice, followed by 
intravenous infusion of 4×106 CD22- CAR T cells (average 
transduction ~51.3%) or mock- IC T cells (average trans-
duction ~54.2%) 2 weeks later. B- ALL engraftment was 
monitored in PB every other week. BM aspirates were 
analyzed 6 weeks after transplantation and at sacrifice, 
along with spleens. Red blood cell counts were deter-
mined with a hemocytometer 2800VET V- Sight (Mena-
rini Diagnostics, Badalona, Spain).
Statistical analysis
All data are expressed as the mean±SEM. Differences 
between groups were assessed using two- tailed unpaired 
Student’s t- tests, or paired Student’s t- tests when 
analyzing data from different donors, unless otherway 
stated. All analyses were performed with Prism software, 
V.8.0 (GraphPad software, San Diego, California, USA).
RESULTS
hCD22.7-CAR T cells efficiently eliminate B-ALL cells in vitro
Our novel anti- CD22 scFv (clone hCD22.7) was cloned 
into a second- generation CAR construct consisting of 
an anti- CD22 scFv, a CD8 hinge/TM spacer, and intra-
cellular signaling domains from 4- 1BB and CD3ζ, 
coupled in- frame with GFP through a T2A sequence 
(figure 1A). To identify the domain of CD22 recognized 
Figure 1 Design, detection and expansion of hCD22.7- CAR T cells. (A) Scheme of the hCD22.7- CAR structure and the mock- 
IC. (B) Histogram showing the blocking of the binding of the anti- CD22 S- HCL-1 clone (PE signal) when CD22+ B cell line Raji 
cells are preincubated with the hCD22.7 clone (left panel). Right panel depicts the CD22 structure, indicating the binding site 
of hCD22.7 scFv (as well as m971, HA22 and BL22 scFvs). (C) Structural model of the CD22- hCD22.7–scFv complex. The 
structure is predicted based on the identified binding epitope of CD22 (ESTKDGKVP, in red) and the sequence of the heavy 
and light chains of the hCD22.7 scFv (blue and pink, respectively). (D) Representative CAR detection in primary T cells. CD22- 
CAR- transduced T cells are detected as GFP+ and are corecognized by an anti- human IgG F(ab')2 and an anti- His moAb (on 
incubation with rCD22- His). (E) Proper T cell activation determined by CD25 and CD69 staining after 48 hours exposure to anti- 
CD3/CD28 (PBMCs from n=3 healthy donors). (F) Robust expansion of activated T cells untransduced or transduced with either 
mock- IC or CD22- CAR (PBMCs from n=3 healthy donors). Plot shows mean±SEM (n=3 healthy donors). CAR, CD22- chimeric 
antigen receptor; FSC, forward scatter; His, histidine; mock- IC, mock- intracellular; PBMCs, peripheral blood mononuclear cells; 
rCD22- His, recombinant CD22- His; scFv, single- chain variable fragment; TM, transmembrane.
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by the hCD22.7 moAb, we performed a cross- blocking 
assay with the anti- CD22 clone H- SCL-1, known to bind 
to the most distal Ig extracellular domain 1 of CD22.25 
Binding of the labeled H- SCL-1 clone was hindered 
in cells preincubated with the antibody hCD22.7, 
indicating an overlapping binding of both moAbs 
to the most distal Ig domain of CD22 (figure 1B). 
Additionally, conformational epitope mapping assay, 
performed to exactly identify the sequence recog-
nized by the hCD22.7 scFv, revealed that hCD22.7 scFv 
Figure 2 CD22- CAR T cells specifically target and eliminate B- ALL cell lines in vitro. (A) Experimental design of the in vitro 
cytotoxicity assays. (B) Flow cytometry gating strategy was used to analyze cytotoxicity. Alive target cells were identified as 
7AAD–CD3–GFP–CD19+CD10+/CD13+ (CD33+ for MV4-11 cell line). CD22 was not used to avoid confounding detection of target 
cells due to potential antigen loss. Doublets were removed from the analysis. (C) Percentage of alive target cells after 48 hours 
incubation with CD22- CAR T cells at the indicated E:T ratios. Results are normalized respect to mock- IC data (PBMCs from 
n=3 healthy donors). CD22 expression in the different cell lines is shown previously in a histogram. (D) Specificity of CD22- CAR 
using CRISPR- Cas9 generated CD19- KO and CD22- KO SEM cells (PBMCs from n=3 healthy donors). CD22 expression in the 
different cell lines is shown previously in a histogram. (E) Absolute counts of alive target cells measured by FACS in 48 hours 
cytotoxicity assays at 1:1 E:T ratio (PBMCs from n=3 healthy donors). (F) ELISA showing robust secretion of proinflammatory 
cytokines by CD22- CAR T cells after 48 hours exposure to B- ALL and acute myeloid leukemia (AML) cell lines (upper panels) 
and wt, CD19- KO or CD22- KO SEM cell lines (bottom panels, PBMCs from n=3 healthy donors). Data are presented as 
mean±SEM (n=3 healthy donors). *p<0.05, **p<0.01, ***p<0.001. B- ALL, B- cell acute lymphoblastic leukemia; CAR, CD22- 
chimeric antigen receptor; E:T, effector:target ratio; FACS, fluorescence- activated cell sorting; FSC, forward scatter; FSC- A, 
forward scatter- area; FSC- H, forward scatter- high; mock- IC, mock intracellular; PBMCs, peripheral blood mononuclear cells; 
SSC, side scatter; KO, knock- out; MFI, median fluorescence intensity; wt, wild- type.
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specifically binds to the ESTKDGKVP sequence, located 
in the Ig- like V- type domain, the most distal domain of 
CD22, thus confirming results from the cross- blocking 
assay (online supplementary figure 2). The molecular 
docking of this binding was computationally modeled 
(figure 1C and online supplementary file 1). The struc-
tural model inferred a CD22- hCD22.7- scFv complex 
energy of −1407.691 Rosetta score,36 and a binding free 
energy of −16.5615 kcal/mol, using the InterfaceAna-
lyzer.38 These binding affinity parameters were compa-
rable, or even slightly higher than those of the clinically 
approved high- affinity anti- CD22 moAb Epratuzumab 
(−1005.624 Rosetta score and −11.345 kcal/mol, 
respectively).30
Healthy human T cells were successfully transduced with 
both CD22- CAR and mock- IC lentivectors with a trans-
duction efficiency of 20%–50%. The expression of the 
CD22- CAR in T cells was confirmed by codetection of scFv 
and GFP, and by using an anti- His moAb on incubation 
with human rCD22- His (figure 1D). Importantly, activated 
(CD69+CD25+) CD22- CAR T cells (figure 1E) continuously 
expanded >100- fold over a 15- day period, similar to mock- IC 
T cells (figure 1F), demonstrating that hCD22.7- CAR 
expression does not hamper T cell expansion.
CD22- CAR T cells from three different healthy donors 
were then functionally tested in vitro in cytotoxicity assays 
against the B- ALL cell lines NALM6, SEM and REH, 
and the AML cell line MV4-11 as a negative control, at 
increasing E:T ratios (figure 2A). Alive target cells after 
hCD22.7- CAR T cell exposure were identified as 7AAD–
CD3–CD19+CD10+ (or CD13+ in the case of the SEM 
cells and 7AAD–CD3–CD33+ in the case of MV4-11 cells, 
figure 2B). Compared with mock- IC T cells, hCD22.7- CAR 
T cells specifically eliminated CD22+ B- ALL cells, even 
at relatively low E:T ratios (figure 2C). Specificity of the 
hCD22.7- CAR T cells was further demonstrated using 
CRISPR/Cas9- mediated CD19- KO and CD22- KO SEM 
cells (figure 2D). Furthermore, B- ALL cells barely survived 
exposure to hCD22.7- CAR T cells in a 48 hours absolute 
number assay at a 1:1 E:T ratio (figure 2E). hCD22.7- CAR 
T cells produced high levels of the proinflammatory cyto-
kines IL2, TNFα, and IFNγ after coculture with target cells, 
confirming their cytotoxicity (figure 2F).
The expression level of CD22 impacts the in vitro efficiency of 
hCD22.7-CAR T cells in killing B-ALL primary cells
It has been reported that remissions post- CD22- CAR T cell 
therapy are short and are associated with reduced expres-
sion of CD22, whereas high expression of CD22 favors the 
activity of CD22- CAR T cells.22 Moreover, whether CD22–/
dim B- ALL relapses are common after CD22- CAR T cell 
treatment remains controversial.15 21 Given this informa-
tion, we next tested the efficacy of our CD22- CAR T cells in 
vitro, in nine primary B- ALL samples with variable expres-
sion levels of CD22. CD22 median fluorescence intensity 
(MFI) levels above or below the mean value (MFI=6752) 
were used to categorize primary B- ALLs as CD22high or 
CD22low (figure 3A and online supplementary figure 3a). 
Cytotoxicity was measured after 24 hours and 48 hours 
exposure to CD22- CAR/mock- IC T cells (figure 3B and 
online supplementary figure 3b). Overall, hCD22.7- CAR 
T cells significantly eliminated primary B- ALL blasts 
(figure 3C). However, while a sustained cell elimina-
tion of CD22high B- ALL blasts (n=3) by hCD22.7- CAR T 
cells was consistently observed over a 48 hours period 
(figure 3C, left panel), hCD22.7- CAR T cell- mediated killing 
of CD22low B- ALL blasts (n=6), although significant, was 
less robust and occurred in a shorter or delayed cytotoxic 
window (figure 3C, right panel). Nevertheless, a similar 
trend of robust production of the proinflammatory cyto-
kines IL2, TNFα, and IFNγ was observed for all B- ALL 
primary samples, regardless the expression levels of CD22 
(figure 3D), confirming an efficient CD22 recognition and 
killing of B- ALL primary cells by our hCD22.7- CAR T cells.
Membrane-distal CD22 epitope-directed CAR T cells efficiently 
eliminate B-ALL blasts in vivo in clinically relevant patient-
derived xenografts
We next assessed the activity of our hCD22.7- CAR in vivo 
using both CD22high (ALL#1 and ALL#2) and CD22low 
(ALL#10) PDX B- ALL samples (figure 4, online supple-
mentary table 1). NSG mice were intra- BM transplanted 
with 0.5–1.5×106 primary CD22+ B- ALL blasts, followed 
by infusion of 4×106 CD22- CAR/mock- IC T cells 2 weeks 
later. Leukemic engraftment and T cell persistence were 
monitored by FACS biweekly in PB, and analyzed in 
BM and spleen at sacrifice, when any animal developed 
signs of overt disease (figure 4A,B). Of note, the kinetics 
of leukemia reconstitution (aggressiveness) detectable 
between week 4 and 20 post- transplant was unique for each 
PDX, and the engraftment of both CD22high and CD22low 
PDXs tended progressively to increase over time in mock- IC 
T cell- treated mice (figure 4C). Importantly, however, 
hCD22.7- CAR T cells eradicated (ALL#1 and ALL#10) or 
largely controlled (ALL#2) the growth of the both CD22high 
and CD22low B- ALL cells (figure 4C,D). T cell persistence 
adapted to the reconstitution kinetics of each PDX, and 
was detected in all three PDXs, even 26 weeks after CAR 
T cell infusion (range, week 6 (n=15) to week 26 (n=5): 
mock- IC group 2.38%±0.65%–0.34%±0.34%; CAR T cell 
group 2.79%±1.13%–0.14%±0.09%, Figure 4E and online 
supplementary figure 4a- b). Disease control was further 
confirmed at sacrifice in ipsilateral (injected tibia) and 
contralateral (both femurs and non- injected tibia) BM, PB 
and spleen through FACS quantification of tumor burden 
(figure 4F and online supplementary figure 4c), lack of sple-
nomegaly (figure 4G), and signs of hematopoietic displace-
ment (figure 4H). Importantly, persistent leukemic cells at 
sacrifice maintained expression of CD22, likely ruling out 
CAR pressure- mediated antigen loss (figure 4I).
Finally, any engineered scFv of either murine or human 
origin expressed in autologous T cells may be immunogenic 
if presented on MHC- I, because peptides derived from it 
may be recognized as ‘non- self’ antigens by the adaptive 
immune system.39 We have thus compared the immunoge-
nicity capacity of our hCD22.7- scFv side- by- side with that of 
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m97115 and HA2220 clones using the in silico tool NetMHC 
V.4.0 which predicts the affinity of peptides to bind to the 
most representative HLA supertypes. As shown in figure 5, 
we found very similar numbers of total (29, 23 and 26) and 
strong (8, 9 and 6) binding 9- mer peptides for hCD22.7, 
m971 and HA22, respectively.
DISCUSSION/CONCLUSIONS
CD19- CAR T cell therapy has shown indisputable 
potential in R/R B- ALL.9 10 Unfortunately, however, 
40%–60% of patients ultimately relapse because of 
poor CAR T cell persistence or the emergence of CD19– 
B- ALL clones.11 12 Very few therapeutic options exist for 
Figure 3 CD22- CAR T cells efficiently target and eliminate primary B- ALL cells in vitro although the expression level of CD22 
impacts their efficacy. (A) MFI of CD22 in the different primary B- ALL samples used (n=9). The mean value for CD22 MFI was 
used to classify primary B- ALL samples as CD22high (ALL #1 to ALL #3) or CD22low (ALL #4 to ALL #9). (B) Flow cytometry 
gating strategy was used to analyze cytotoxicity. Alive target cells were identified as 7AAD–CD3–GFP–CD19+CD10+. CD22 was 
not used to avoid confounding detection of target cells due to potential antigen loss. Doublets were removed from the analysis. 
(C) Absolute counts of alive target CD22high and CD22low cells measured by FACS in 24 hours and 48 hours cytotoxicity assays 
at 1:1 E:T ratio. The statistical significance is indicated for each sample. A two- way ANOVA test (Sidak’s multiple comparison 
test) was used. (D) ELISA showing a similar robust production of IL2, TNFα, and IFNγ by CD22- CAR T cells after 48 hours 
exposure, among all B- ALL primary samples regardless the expression levels of CD22. Data are presented as mean±SEM 
(PBMCs from n=3 healthy donors). *p<0.05, **p<0.01. ANOVA, analysis of variance; B- ALL, B- cell acute lymphoblastic leukemia; 
CAR, CD22- chimeric antigen receptor; E:T, effector:target ratio; FACS, fluorescence- activated cell sorting; MFI, median 
fluorescence intensity; FSC, forward scatter; FSC- A, forward scatter- area; FSC- H, forward scatter- high; PBMCs, peripheral 
blood mononuclear cells; SSC, side scatter.
 on F













8 Velasco- Hernandez T, et al. J Immunother Cancer 2020;8:e000896. doi:10.1136/jitc-2020-000896
Open access 
CD19– B- ALL relapse,40 41 and novel strategies, including 
the development of new target antigens, are being explored 
to enhance CAR T cell function and persistence.13 42 CD22 
is a pan B- cell antigen,14 and is an attractive alternative to 
CD19 for CAR T cell therapy because it will target CD19– 
relapses, which usually retain CD22 expression.
Figure 4 CAR T cells directed against a distal membrane CD22 epitope efficiently eliminate differentially aggressive PDX B- 
ALL blasts in vivo. (A) Experimental design of the in vivo experiments. (B) Gating strategy used to analyze FACS data from the 
in vivo experiments. Leukemic cells were identified as hCD45+hHLA- ABC+hCD3–hCD19+hCD10+. CD22 was excluded from the 
identification to avoid confounding analysis due to potential antigen loss. CAR T cells were identified based on CD3 and GFP 
expression. Doublets were removed from the analysis. (C) Leukemic burden measured in PB over a 26 week follow- up period 
(n=4–5 mice/group; n=3 PDXs, CD22high (ALL#1 and ALL#2) and CD22low (ALL#10)). (D) Disease- free survival curves of mice 
transplanted with the three patient derived xenograft (PDXs). A mouse was considered ‘with disease’ when presenting >0.1% 
blasts in PB. (E) T cell persistence measured in PB of mice transplanted with the three PDXs. (F) Leukemic burden at sacrifice in 
PB, ipsilateral and contralateral BM and spleen (n=9 mice from the ALL#2 PDX). Each mouse is identified with the same number 
across the plots. Macroscopic images of these spleens are also shown. (G) Spleen weight (total animals, n=14) from mock- IC 
and CD22- CAR T cell- treated mice at sacrifice. (H) PB RBC counts in mock- IC and CD22- CAR T cell- treated mice at sacrifice 
(n=14). (I) CD22 MFI of persistent primary B- ALL in mock- IC- treated and CD22- CAR T cell- treated mice at sacrifice (ALL#2 
mice, n=4–5) and representative FACS plots of contralateral BM samples showing the levels of CD22 of a mock- IC and a CD22- 
CAR T cell- treated mouse within the target cell population. Plot shows mean±SEM. *p<0.05, **p<0.01, ***p<0.001. B- ALL, B- cell 
acute lymphoblastic leukemia; BM, bone marrow; CAR, CD22- chimeric antigen receptor; D, day; FACS, fluorescence- activated 
cell sorting; PB, peripheral blood; it, intratibia; iv, intravenous; MFI, median fluorescence intensity; mock- IC, mock intracellular; 
RBC, red blood cell; W, week.
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In this line, several CD22- CARs have been reported to 
induce clinical remission in 60%–70% of patients with R/R 
B- ALL either naive or resistant to CD19- CAR T cells.15 20–22 
But, phase I clinical studies based on different CD22 scFvs 
(m971 vs YK- CD22BB-002) have reported preliminary 
results concerning CD22 loss and immune escape on 
CD22- CAR T cell treatment.15 21 A previous comprehen-
sive comparison of several anti- CD22 moAbs indicated that 
epitope selection is crucial for the antileukemic activity 
of the CD22- CAR, and that the m971 scFv, which targets 
the most membrane- proximal Ig extracellular domains of 
CD22 (5 to 7), seems more potent than BL22 and HA22 
scFvs, which target the proximal Ig domain 3.20 In this 
study, we report the generation and preclinical develop-
ment of a new CD22- CAR that contributes to the limited 
state- of- the- art arsenal of CD22- CARs. Three CD22 reactive 
hybridomas were generated using conventional moAb 
generation techniques, rendering three very specific IgG1 
isotype anti- CD22 moAbs, finally selecting the hCD22.7 
clone for the construction of the CAR. To the best of our 
knowledge, this ab initio generated hCD22.7 scFv is the first 
used for the development of a CD22- CAR recognizing the 
most membrane- distal Ig extracellular domain 1 of CD22. 
Additionally, we provide an uncommon comprehensive 
characterization including the molecular docking, epitope 
mapping, binding affinity, and immunogenicity of the 
hCD22.7 scFv.
Previous studies have addressed the impact of antigen 
density on CD22- CAR T cell efficacy using a higher- affinity 
version of the m971 scFv, and reported a positive correla-
tion between CD22 expression and the functionality of 
CD22- CAR T cells, both in vitro and in vivo, using cell 
Figure 5 Immunogenic prediction of hCD22.7- scFv. The immunogenic potential of hCD22.7, m971 and HA22 CD22- scFvs 
was compared by in silico prediction analysis. CD22- scFvs were broken in 9- mer peptides, length for which human leukocyte 
antigen (HLA) molecules have a strong preference. Peptides are considered to bind MHC- I when a IC50 is <500 nM, being 
considered strong binders when IC50 <50 nM (affinity value >2, dotted line) and amino acid sequence is shown in the figure. Only 
the most representative HLA supertypes were analyzed. The predicted epitope- binding affinity was calculated as 1/IC50 100. 
Predicted epitopes are distributed along the x- axis according to their distribution in the protein. IC50, half- maximum inhibitory 
concentration; scFv, single- chain variable fragment.  on F
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lines and one patient derived xenograft (PDX).22 Here, 
the expression level of CD22 was used to classify primary 
B- ALL samples as CD22high or CD22low, and we show that 
although our high- affinity hCD22.7- CAR efficiently and 
consistently targeted CD22+ cells, it displayed a differ-
ential killing kinetics depending on the expression level 
of CD22. While a sustained cell elimination of CD22high 
cells was observed over a 48 hours period, a shorter or 
delayed but still efficient cytotoxic window was observed 
for CD22low cells. It is also plausible that CD22 adopts 
different conformational epitope exposures43 affecting 
the performance of the CAR T cells in the different 
samples. Of note, a robust production of proinflamma-
tory cytokines was observed for all B- ALL primary samples, 
regardless the expression levels of CD22, confirming an 
efficient CD22 recognition and killing of B- ALL primary 
cells by our hCD22.7- CAR T cells.
Our membrane distal epitope hCD22.7- CAR T cells 
performed competently in controlling in vivo several 
B- ALL PDXs with varied aggressiveness for a long period, 
which was coupled to long- term T cell persistence. In fact, 
hCD22.7- CAR T cells were capable of eradicating long- 
term disease in several PDXs, with persistence of T cells 
even after 26 weeks. In the PDX ALL#2, although the 
leukemia burden was not fully eradicated, it was signifi-
cantly controlled. The not complete eradication of this 
PDX may reflect a more aggressive molecular subtype, a 
superior intrinsic refractoriness due to resistance gener-
ated through multiple lines of previous treatments, a 
faster/deeper graft of this particular PDX, a worse phar-
macodynamics of CAR T cells in this particular case 
perhaps due to peripheral filtration, and so on. Of note, 
we found no apparent signs of CD22 antigen loss by the 
few surviving/resistant B- ALL cells in vivo. Antigen loss 
represents one non- exclusive potential mechanism of 
immune escape and largely relies on tumor- specific cell- 
autonomous properties, differentiation stage in which 
leukemic cells are stalled, and the complexity of immune 
cellular and soluble interactions, difficult to reconstruct 
in xenograft models. In addition, it cannot be ruled out 
that residual CAR- resistant CD22+ leukemic cells have 
simply not been encountered by CD22- CAR T cells. Only 
a controlled and homogeneous phase I clinical trial will 
reliably inform about a potential target antigen loss and 
immune scape. Technically, our experimental design 
used a rigorous ‘mock’ control where all the structural, 
cytolytic and costimulatory motifs are expressed in the 
effector T cells, but without the extracellular anti- CD22 
scFv region. This intracellular mock further validates the 
specificity and sensitivity of our hCD22.7- CAR.
Our hCD22.7- derived membrane distal- targeting CAR 
has not been functionally compared side- by- side with 
other membrane proximal- targeting CD22- scFvs used 
already in clinical trials,15 21 with which Fry et al published 
discrete complete remission (CR) rates of 57% with a 
median remission duration of 6 moths in patients with 
R/R B- ALL treated with m971- CD22- CAR T cells15 and 
in a more recent study they reported CR of 70% with a 
median relapse- free survival of 6 months.23 However, the 
hCD22.7- CAR performs efficiently in vitro and in vivo 
using clinically relevant patient samples of B- ALL with 
different aggressiveness. This coupled to the long- term 
persistence of hCD22.7- CAR T cells, the lack of antigenic 
loss in vivo in the few CAR- resistant B- ALL cells, its high 
affinity, and its immunogenicity similar to m971 and 
HA22 CD22- scFvs provides support for its clinical valida-
tion as either single or tandem CD22–CD19- CAR for both 
naive and anti- CD19- resistant patients with B- ALL.
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